ABOLOGIX founded in Geneva, Switzerland

Geneva, Switzerland, January 25, 2018.


Abologix was launched today, and it is the newest addition to the biotechnology ecosystem in the city of Geneva (Switzerland).


The three founders of Abologix are Dr.Ignacio Faus, Prof. Beat Imhof and Prof. Thomas Matthes.The company intends to develop novel monoclonal antibodies for the treatment of JAM-C positive hematological tumours.New therapeutics for the treatment of difficult to manage solid tumours will de developed by blocking the Olfml3 target.


Dr. Ignacio Faus has been named Chairman of the Board of the company. He has more than 20+ years of experience in the pharmaceutical and biotechnology industries, in companies both in the USA and in Europe.


Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3) for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Genevaand the Hôpitaux Universitaires de Genève.

ABOLOGIX awarded a two year Innosuisse Innovation

Geneva, Switzerland, Juy 24, 2020. Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner

Copyright © 2021 ABOLOGIX